TLR7 and neoplasm: In murine nonepithelial tumours, CD-40/TLR-7 agonists have been utilized as adjuvants in vaccination with exogenous tumour antigen, which resulted in stronger and less toxic antitumour memory T-cell responses compared to monotherapy [52].